Skip to main content

Table 1 Patients' clinical characteristics and outcomesa

From: Hormonal status in protracted critical illness and in-hospital mortality

Patient demographics, N= 102 (100%)

Data

Median age, yr (IQR)

66 (51 to 78)

COPDb, n (%)

39 (38%)

Chronic cardiac insufficiencyb, n (%)

28 (27.5%)

Medical admission, n (%)

71 (69.6%)

Median SAPS II at ICU admission (IQR)

46 (38 to 55)

From admission to awakening (day 1)

 

   Septic shockc, n (%)

53 (52%)

   Median days with failure of ≥2 organsd, days (IQR)

8 (7 to 11)

   Median duration of mechanical ventilation, days (IQR)

10.0 (8.0 to 14.0)

   Mean blood glucose, mM/l (IQR)

7.6 (6.9 to 8.8)

   Use of vasopressors, n (%)

77 (75%)

   Use of corticosteroids, n (%)

64 (63%)

   Median corticosteroid dose, 103 g (IQR)

1.0 (0 to 1.9)

   Median delay from steroid administration to day 1, days (IQR)

3.0 (1.0 to 8.0)

   Use of NMBA, n (%)

40 (39%)

At awakening (day 1, n = 86)

 

   Median SAPS II (IQR)

30 (23 to 26)

After awakening

 

   Median ICU length of stay, days (IQR)

23 (15 to 35)

   ICU mortality, n (%)

15 (15%)

   In-hospital mortality, n (%)

24 (24%)

  1. aIQR, interquartile range; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; SAPS II, Simplified Acute Physiology Score II [15]; NMBA, neuromuscular blocking agent; bdiagnosis of COPD and chronic cardiac insufficiency were based on clinical history; cseptic shock was defined as the administration of catecholamines and a concomitant documented infection after exclusion of other causes of shock; drenal, hepatic, and hematological failure were defined according to the Organ Dysfunctions and/or Infection score [16].